RUBY Overzicht aandelen
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
Rubius Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$0.057 |
| 52 Week Hoogtepunt | US$0.38 |
| 52 Week Laag | US$0.0032 |
| Bèta | 2.21 |
| 11 maand verandering | 198.43% |
| 3 maanden verandering | 251.85% |
| 1 Jaar Verandering | -64.38% |
| 33 jaar verandering | -99.32% |
| 5 jaar verandering | -99.63% |
| Verandering sinds IPO | -99.76% |
Recent nieuws en updates
Recent updates
Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03
Aug 09Rubius: Poor Data, Punishing Environment, Beaten Stock
Jun 19Rubius Looks Attractive Before AACR Data Readout
Mar 21Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?
Oct 28
Our Read On Rubius Therapeutics
Jul 11Rubius Therapeutics EPS beats by $0.02
May 10Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?
Feb 25Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow
Jan 14Rubius Therapeutics EPS misses by $0.01
Nov 09Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers
Oct 28Rendement voor aandeelhouders
| RUBY | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 2.7% | -0.7% | -1.6% |
| 1Y | -64.4% | 19.8% | 30.8% |
Rendement versus industrie: RUBY underperformed the US Biotechs industry which returned 7.1% over the past year.
Rendement versus markt: RUBY underperformed the US Market which returned 22.4% over the past year.
Prijsvolatiliteit
| RUBY volatility | |
|---|---|
| RUBY Average Weekly Movement | 54.6% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: RUBY's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: RUBY's weekly volatility has increased from 34% to 55% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2013 | 6 | Craig Jalbert | www.rubiustx.com |
Rubius Therapeutics, Inc. Samenvatting
| RUBY fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$5.16m |
| Inkomsten(TTM) | -US$179.67m |
| Inkomsten(TTM) | n/a |
0.0x
P/S-verhouding0.0x
Koers/WinstverhoudingIs RUBY overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| RUBY resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$0 |
| Kosten van inkomsten | US$0 |
| Brutowinst | US$0 |
| Overige uitgaven | US$179.67m |
| Inkomsten | -US$179.67m |
Laatst gerapporteerde inkomsten
Dec 31, 2022
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.99 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde RUBY op de lange termijn?
Bekijk historische prestaties en vergelijking